Inhibition of Integrin Alphavbeta3 Prevents Urokinase Plasminogen Activator-mediated Impairment of Cerebrovasodilation After Cerebral Hypoxia/ischemia

Overview

Journal Am J Physiol Heart Circ Physiol

Publisher American Physiological Society

Specialties Cardiology & Vascular Diseases
Physiology

Date 2009 Jan 27

PMID 19168722

Citations 5

Authors

J Willis Kiessling

Douglas B Cines

Abd Al-Roof Higazi

William M Armstead

Affiliations

Soon will be listed here.

Abstract

Cerebral hypoxia (10 min) followed immediately by ischemia (20 min) (H/I) impairs cerebrovasodilation in response to hypercapnia and hypotension in the newborn pig; exogenous urokinase plasminogen activator (uPA) potentiates this effect, whereas the blockade of endogenous uPA-mediated vasoactivity prevents it completely. This study investigated the role of integrin alpha(V)beta(3) in the uPA-mediated impairment of cerebrovasodilation after H/I in piglets equipped with a closed cranial window. Pial artery dilation induced by hypercapnia (Pco(2), 75 mmHg) and hypotension (mean arterial blood pressure, decreased by 45%) was blunted after H/I, reversed to vasconstriction in piglets treated with uPA (10(-7) M), a concentration observed in cerebrospinal fluid after H/I, but reverted to a dilation no different than preinsult in piglets administered an anti-alpha(V)beta(3) antibody (10 ng/ml) in addition to uPA (26 +/- 1, 9 +/- 1, -10 +/- 3, and 22 +/- 3% for hypercapnia before H/I, after H/I, after H/I with uPA, and after H/I with combined uPA and anti-alpha(V)beta(3) antibody, respectively). Responses to isoproterenol were unchanged after H/I and combined uPA and anti-alpha(V)beta(3) antibody. Similar results were obtained for the combined administration of uPA with the alpha(V)beta(3) antagonist Arg-Gly-Asp-d-Phe-Val and Arg-Gly-Asp-Ser, but not for the inactive analog Arg-Gly-Asp-Glu-Ser acetate. These data show that the activation of the integrin alpha(V)beta(3) contributes to the uPA-mediated impairment of pial artery dilation after H/I. These data suggest that the inhibition of uPA and integrin signaling may preserve cerebrohemodynamic control after H/I.

Citing Articles

Pathophysiology of Cerebral Hyperperfusion in Term Neonates With Hypoxic-Ischemic Encephalopathy: A Systematic Review for Future Research.

Kleuskens D, Costa F, Annink K, van den Hoogen A, Alderliesten T, Groenendaal F Front Pediatr. 2021; 9:631258.

PMID: 33604320 PMC: 7884860. DOI: 10.3389/fped.2021.631258.

Ischemic preconditioning protects against ischemic brain injury.

Ma X, Liu M, Liu Y, Ma L, Jiang Y, Chen X Neural Regen Res. 2016; 11(5):765-70.

PMID: 27335560 PMC: 4904467. DOI: 10.4103/1673-5374.182703.

Effects of integrins and integrin αvβ3 inhibitor on angiogenesis in cerebral ischemic stroke.

Bi J, Yi L J Huazhong Univ Sci Technolog Med Sci. 2014; 34(3):299-305.

PMID: 24939290 DOI: 10.1007/s11596-014-1274-4.

PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.

Armstead W, Riley J, Kiessling J, Cines D, Higazi A Am J Physiol Heart Circ Physiol. 2010; 299(1):H76-80.

PMID: 20435843 PMC: 2904139. DOI: 10.1152/ajpheart.00185.2010.

Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.

Armstead W, Ganguly K, Kiessling J, Riley J, Chen X, Smith D J Neurochem. 2010; 113(2):303-12.

PMID: 20405577 PMC: 3467975. DOI: 10.1111/j.1471-4159.2010.06613.x.

References

Kraus F, Acheen V . Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Hum Pathol. 1999; 30(7):759-69. DOI: 10.1016/s0046-8177(99)90136-3. View

Nelson K, Lynch J . Stroke in newborn infants. Lancet Neurol. 2004; 3(3):150-8. DOI: 10.1016/S1474-4422(04)00679-9. View

Armstead W, Cines D, Bdeir K, Kulikovskaya I, Stein S, Higazi A . uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res. 2008; 1231:121-31. PMC: 2572778. DOI: 10.1016/j.brainres.2008.06.115. View

Armstead W, Cines D, Higazie A . Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Brain Res Dev Brain Res. 2005; 156(2):139-46. DOI: 10.1016/j.devbrainres.2005.02.012. View

Akkawi S, Nassar T, Tarshis M, Cines D, Higazi A . LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol. 2006; 291(3):H1351-9. DOI: 10.1152/ajpheart.01042.2005. View

Higazi A, Mazar A, Wang J, Reilly R, Henkin J, Kniss D . Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood. 1996; 87(9):3545-9. View

Nassar T, Haj-Yehia A, Akkawi S, Kuo A, Bdeir K, Mazar A . Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem. 2002; 277(43):40499-504. DOI: 10.1074/jbc.M207172200. View

Higazi A, Bdeir K, Hiss E, Arad S, Kuo A, Barghouti I . Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. Blood. 1998; 92(6):2075-83. View

Jagolino A, Armstead W . PTK, MAPK, and NOC/oFQ impair hypercapnic cerebrovasodilation after hypoxia/ischemia. Am J Physiol Heart Circ Physiol. 2002; 284(1):H101-7. DOI: 10.1152/ajpheart.00457.2002. View

10.

Tarui T, Akakura N, Majumdar M, Andronicos N, Takagi J, Mazar A . Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost. 2006; 95(3):524-34. DOI: 10.1160/TH05-06-0457. View

11.

Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie E . The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001; 7(1):59-64. DOI: 10.1038/83358. View

12.

Sughrue M, Mehra A, Connolly Jr E, DAmbrosio A . Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: a critical review of the literature. Inflamm Res. 2004; 53(10):497-508. DOI: 10.1007/s00011-004-1282-0. View

13.

Gunther G, Junker R, Strater R, Schobess R, Kurnik K, Heller C . Symptomatic ischemic stroke in full-term neonates : role of acquired and genetic prothrombotic risk factors. Stroke. 2000; 31(10):2437-41. DOI: 10.1161/01.str.31.10.2437. View

14.

Wang Y, Tsirka S, Strickland S, Stieg P, Soriano S, Lipton S . Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998; 4(2):228-31. DOI: 10.1038/nm0298-228. View

15.

Volpe J . Brain injury in the premature infant: overview of clinical aspects, neuropathology, and pathogenesis. Semin Pediatr Neurol. 1998; 5(3):135-51. DOI: 10.1016/s1071-9091(98)80030-2. View

16.

Hosomi N, Lucero J, Heo J, Koziol J, Copeland B, Del Zoppo G . Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke. 2001; 32(6):1341-8. DOI: 10.1161/01.str.32.6.1341. View

17.

NASSAR T, Sachais B, Kuo A, Bdeir K, Al-Mehdi A, Mazar A . Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo. FASEB J. 2000; 14(10):1411-22. DOI: 10.1096/fj.14.10.1411. View

18.

Nisato R, Tille J, Jonczyk A, Goodman S, Pepper M . alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis. 2004; 6(2):105-19. DOI: 10.1023/B:AGEN.0000011801.98187.f2. View

19.

Hayashi T, Sakai K, Sasaki C, Zhang W, Warita H, Abe K . c-Jun N-terminal kinase (JNK) and JNK interacting protein response in rat brain after transient middle cerebral artery occlusion. Neurosci Lett. 2000; 284(3):195-9. DOI: 10.1016/s0304-3940(00)01024-7. View

20.

Shimamura N, Matchett G, Yatsushige H, Calvert J, Ohkuma H, Zhang J . Inhibition of integrin alphavbeta3 ameliorates focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. Stroke. 2006; 37(7):1902-9. DOI: 10.1161/01.STR.0000226991.27540.f2. View